癌症诊断市场机会、成长驱动因素、产业趋势分析及预测（2026-2035年）

2025 年全球癌症诊断市场价值为 1,717 亿美元，预计到 2035 年将以 9.1% 的复合年增长率增长至 4,089 亿美元。

癌症发生率的上升以及能够精准检测疾病的先进诊断技术的日益普及推动了市场扩张。癌症诊断涵盖了旨在识别癌症类型、分期和位置的多种技术、流程和检测方法，从而支持早期治疗并改善预后。个人化医疗的创新，特别是生物标记驱动的方法，正在改变癌症的检测、监测和治疗方案的选择。诸如液体活检等非侵入性方法能够即时监测治疗反应并早期发现肿瘤，从而推动了医疗机构对这些技术的采用。先进的影像技术、人工智慧辅助诊断工具和实验室检测技术进一步提高了诊断的准确性和可靠性，促进了这些技术在全球医院和诊断中心的广泛应用。这些技术的整合也加速了临床研究和治疗方案的最佳化，从而支持了整体市场成长。

到2025年，影像领域将占据63.4%的市场。癌症病例的不断增加推动了对诊断影像的需求，这对于早期发现和精准治疗方案的发展至关重要。 PET-CT、MRI和人工智慧辅助成像等创新技术正在提高诊断精度，从而促进影像技术在全球的应用。

预计到2025年，医院板块的收入将达到695亿美元。该板块的增长主要得益于医院数量的增加、城市化进程的加快以及操作先进诊断系统的熟练人员的涌现。此外，医院还提供包括影像、活检和液体活检平台在内的先进技术，从而支持全面的癌症诊断并改善患者的治疗效果。

预计到2025年，北美癌症诊断市占率将达到40.5%。高癌症发病率、强劲的研究投入以及先进的医疗基础设施正在推动市场扩张。製药公司、生技公司和研究机构正大力投资创新诊断解决方案，进一步促进了该地区的成长。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

• 产业生态系分析
• 产业影响因素
  • 成长驱动因素
    • 全球癌症发生率不断上升
    • 政府和其他组织开展了多项倡议，以提高公众对疾病的认识。
    • 发展中国家的诊断实验室数量不断增加
    • 癌症诊断技术进步
  • 产业陷阱与挑战
    • 诊断影像系统需要高额的资本投入和高昂的成本。
    • 高辐射暴露带来的风险会影响CT扫描仪的使用。
  • 市场机会
    • 新兴市场的区域扩张
    • 人工智慧与数位病理学的融合
• 成长潜力分析
• 监管环境
  • 北美洲
  • 欧洲
  • 亚太地区
• 技术格局
  • 当前技术趋势
  • 新兴技术
• 专利分析
• 2025年定价分析
• 未来市场趋势
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 全球的
  • 北美洲
  • 欧洲
  • 亚太地区
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键发展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场估算与预测：依应用领域划分，2022-2035年

• 肿瘤生物标记检测
• 影像
  • 超音波和放射学
  • 乳房X光检查
  • 核磁共振扫描
  • PET扫描
  • CT扫描
  • SPECT 和其他影像技术
• 活检
• 液体活检
• 免疫组织化学
• 原位杂交

第六章：市场估计与预测：依癌症类型划分，2022-2035年

• 膀胱癌
• 乳癌
• 结肠癌和直肠癌
• 子宫内膜癌
• 肾癌
• 白血病
• 肝癌和肺癌
• 黑色素瘤
• 非何杰金氏淋巴瘤
• 胰腺癌
• 摄护腺癌
• 甲状腺癌
• 其他癌症类型

第七章：市场估算与预测：依最终用途划分，2022-2035年

• 医院
• 诊断实验室
• 诊断影像中心
• 癌症研究机构

第八章：市场估算与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋

第九章：公司简介

• Abbott Laboratories
• Becton, Dickinson and Company
• Biocare Medical
• Biocartis
• Biomerieux
• Bio-Rad Laboratories
• Danaher Corporation
• Exact Sciences Corporation
• F-Hoffmann-La Roche
• GE HealthCare Technologies
• Guardant Health
• Hologic
• Koninklijke Philips
• QIAGEN
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific

The Global Cancer Diagnostics Market was valued at USD 171.7 billion in 2025 and is estimated to grow at a CAGR of 9.1% to reach USD 408.9 billion by 2035.

Market expansion is fueled by the rising prevalence of cancer and the growing adoption of advanced diagnostic technologies that enable precise disease detection. Cancer diagnostics encompass a wide range of technologies, processes, and tests designed to identify the type, stage, and location of cancer, supporting early treatment and better outcomes. Innovations in personalized medicine, particularly biomarker-driven approaches, are transforming detection, monitoring, and therapy selection. Non-invasive methods such as liquid biopsies allow real-time monitoring of treatment responses and early detection of tumors, driving adoption among healthcare providers. Advanced imaging, AI-assisted diagnostic tools, and lab-based testing techniques are further enhancing accuracy and reliability, encouraging widespread uptake in hospitals and diagnostic centers globally. The integration of these technologies is also accelerating clinical research and treatment optimization, supporting overall market growth.

The imaging segment held a 63.4% share in 2025. The rising number of cancer cases is increasing demand for diagnostic imaging, which is essential for early detection and precise treatment planning. Innovations such as PET-CT, MRI, and AI-assisted imaging are improving accuracy, boosting the adoption of imaging technologies worldwide.

The hospitals segment generated USD 69.5 billion in 2025. The growth of this segment is driven by increasing hospital numbers, urbanization, and the availability of skilled personnel to operate advanced diagnostic systems. Hospitals also offer access to advanced technologies, including imaging, biopsies, and liquid biopsy platforms, supporting comprehensive cancer diagnostics and improved patient outcomes.

North America Cancer Diagnostics Market held a 40.5% share in 2025. High cancer prevalence, coupled with strong research initiatives and advanced healthcare infrastructure, is driving market expansion. Pharmaceutical companies, biotechnology firms, and research institutions are heavily investing in innovative diagnostic solutions, further supporting growth in the region.

Key players in the Global Cancer Diagnostics Market include Guardant Health, Abbott Laboratories, Thermo Fisher Scientific, Biocare Medical, Bio-Rad Laboratories, Biomerieux, Danaher Corporation, Siemens Healthineers, Hologic, QIAGEN, GE HealthCare Technologies, Becton Dickinson and Company, Biocartis, F. Hoffmann-La Roche, and Koninklijke Philips.

Companies in the Global Cancer Diagnostics Market are implementing multiple strategies to strengthen their market presence and competitive positioning. They are investing heavily in R&D to develop next-generation diagnostic solutions, including AI-assisted imaging, liquid biopsy platforms, and biomarker-focused tests. Strategic collaborations, partnerships, and acquisitions help expand geographic reach and technological capabilities. Firms are also enhancing product portfolios by introducing innovative, high-precision diagnostic tools that improve early detection and treatment monitoring. Additionally, companies are targeting emerging markets, optimizing manufacturing processes, and offering comprehensive customer support and training to increase adoption in hospitals and diagnostic centers, while maintaining strong regulatory compliance and supply chain efficiency.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Application trends
  • 2.2.3 Cancer type trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer globally
    • 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
    • 3.2.1.3 Growing number of diagnostic laboratories in developing countries
    • 3.2.1.4 Technology advancements in cancer diagnostics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High capital investment coupled with high costs associated with diagnostic imaging systems
    • 3.2.2.2 Risk related with high radiation exposure affecting use of CT scanner
  • 3.2.3 Market opportunities
    • 3.2.3.1 Regional expansion in emerging markets
    • 3.2.3.2 Integration of AI and digital pathology
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Patent analysis
• 3.7 Pricing analysis, 2025
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key development
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Tumor biomarkers tests
• 5.3 Imaging
  • 5.3.1 Ultrasound and radiology
  • 5.3.2 Mammography
  • 5.3.3 MRI scan
  • 5.3.4 PET scan
  • 5.3.5 CT scan
  • 5.3.6 SPECT and other imaging
• 5.4 Biopsy
• 5.5 Liquid biopsy
• 5.6 Immunohistochemistry
• 5.7 In situ hybridization

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Bladder cancer
• 6.3 Breast cancer
• 6.4 Colon and rectal cancer
• 6.5 Endometrial cancer
• 6.6 Kidney cancer
• 6.7 Leukemia
• 6.8 Liver and lung cancer
• 6.9 Melanoma
• 6.10 Non-Hodgkin lymphoma
• 6.11 Pancreatic cancer
• 6.12 Prostate cancer
• 6.13 Thyroid cancer
• 6.14 Other cancer types

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Diagnostic imaging centers
• 7.5 Cancer research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Becton, Dickinson and Company
• 9.3 Biocare Medical
• 9.4 Biocartis
• 9.5 Biomerieux
• 9.6 Bio-Rad Laboratories
• 9.7 Danaher Corporation
• 9.8 Exact Sciences Corporation
• 9.9 F-Hoffmann-La Roche
• 9.10 GE HealthCare Technologies
• 9.11 Guardant Health
• 9.12 Hologic
• 9.13 Koninklijke Philips
• 9.14 QIAGEN
• 9.15 Siemens Healthineers
• 9.16 Sysmex Corporation
• 9.17 Thermo Fisher Scientific